Cyclo Therapeutics, Inc.
CYTH
$0.7206
$0.00991.39%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 870.80K | 1.13M | 1.13M | 1.08M | 951.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 870.80K | 1.13M | 1.13M | 1.08M | 951.80K |
| Cost of Revenue | 76.20K | 95.50K | 101.20K | 98.40K | 94.60K |
| Gross Profit | 794.60K | 1.04M | 1.03M | 978.00K | 857.20K |
| SG&A Expenses | 9.49M | 8.23M | 7.53M | 6.83M | 7.01M |
| Depreciation & Amortization | 11.40K | 14.00K | 16.60K | 19.20K | 19.30K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.55M | 22.29M | 21.28M | 21.13M | 20.34M |
| Operating Income | -24.68M | -21.15M | -20.15M | -20.05M | -19.39M |
| Income Before Tax | -24.80M | -20.74M | -19.39M | -20.06M | -19.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -24.80 | -20.74 | -19.39 | -20.06 | -19.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.80M | -20.74M | -19.39M | -20.06M | -19.40M |
| EBIT | -24.68M | -21.15M | -20.15M | -20.05M | -19.39M |
| EBITDA | -24.67M | -21.14M | -20.14M | -20.03M | -19.37M |
| EPS Basic | -0.92 | -0.91 | -1.03 | -1.33 | -1.67 |
| Normalized Basic EPS | -0.52 | -0.55 | -0.64 | -0.83 | -1.04 |
| EPS Diluted | -0.92 | -0.91 | -1.03 | -1.33 | -1.67 |
| Normalized Diluted EPS | -0.52 | -0.55 | -0.64 | -0.83 | -1.04 |
| Average Basic Shares Outstanding | 108.09M | 95.55M | 80.95M | 63.37M | 49.71M |
| Average Diluted Shares Outstanding | 108.09M | 95.55M | 80.95M | 63.37M | 49.71M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
